AR101468A1 - Vacuna en vector recombinante de adenovirus aviar serotipo 9 - Google Patents
Vacuna en vector recombinante de adenovirus aviar serotipo 9Info
- Publication number
- AR101468A1 AR101468A1 ARP150102532A ARP150102532A AR101468A1 AR 101468 A1 AR101468 A1 AR 101468A1 AR P150102532 A ARP150102532 A AR P150102532A AR P150102532 A ARP150102532 A AR P150102532A AR 101468 A1 AR101468 A1 AR 101468A1
- Authority
- AR
- Argentina
- Prior art keywords
- adenovirus
- serotype
- disease
- interest
- antigen
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 4
- 229940126580 vector vaccine Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 5
- 125000003729 nucleotide group Chemical group 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 241000701792 avian adenovirus Species 0.000 abstract 2
- 229940124551 recombinant vaccine Drugs 0.000 abstract 2
- 208000006758 Marek Disease Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Vacuna recombinante que comprende un vector de adenovirus aviar serotipo 9 (FAdV-9) que tiene insertada por lo menos una secuencia de nucleótidos exógena que codifica para por lo menos un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus, y un vehículo, adyuvante y/o excipiente farmacéuticamente aceptable, en donde la secuencia de nucleótidos exógena que codifica para por lo menos un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus se localiza entre los nucleótidos 491-2782. Reivindicación 15: La vacuna recombinante de conformidad con la reivindicación 1, caracterizada además porque comprende una vacuna de virus completo contra la enfermedad de Marek. Reivindicación 18: Una semilla maestra de un virus recombinante de adenovirus aviar serotipo 9 (FAdV-9) que tiene insertada una secuencia de nucleótidos exógena que codifica para un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus, localizada entre los nucleótidos 491-2782, caracterizada porque es obtenida después de 6 a 11 pases en cultivo celular.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2014/063809 WO2016020730A1 (es) | 2014-08-08 | 2014-08-08 | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101468A1 true AR101468A1 (es) | 2016-12-21 |
Family
ID=55263220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102532A AR101468A1 (es) | 2014-08-08 | 2015-08-07 | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10758608B2 (es) |
EP (1) | EP3178938A4 (es) |
JP (1) | JP2017526737A (es) |
KR (1) | KR20170063552A (es) |
CN (1) | CN106661592A (es) |
AR (1) | AR101468A1 (es) |
BR (1) | BR112017002577A2 (es) |
CA (1) | CA2956997A1 (es) |
CO (1) | CO2017001614A2 (es) |
EA (1) | EA038951B1 (es) |
MX (3) | MX2017001742A (es) |
PE (2) | PE20170429A1 (es) |
PH (1) | PH12017500216B1 (es) |
WO (2) | WO2016020730A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011530718A (ja) | 2008-08-08 | 2011-12-22 | スリーエム イノベイティブ プロパティズ カンパニー | 光を管理するための粘弾性層を有する光ガイド |
WO2016020730A1 (es) * | 2014-08-08 | 2016-02-11 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
CN108126191B (zh) * | 2016-12-01 | 2021-04-06 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
CN108653724B (zh) * | 2017-04-01 | 2020-11-27 | 普莱柯生物工程股份有限公司 | 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用 |
CN110680914B (zh) * | 2019-09-23 | 2021-11-26 | 洛阳职业技术学院 | 一种三联灭活疫苗及其制备方法 |
CN111494617A (zh) * | 2020-04-08 | 2020-08-07 | 扬州优邦生物药品有限公司 | 一种四联灭活疫苗及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
DE69435081T2 (de) | 1993-04-14 | 2008-06-12 | Commonwealth Scientific And Industrial Research Organisation | Rekombinanter adenovirusvektor für geflügel |
US6296852B1 (en) | 1993-04-14 | 2001-10-02 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
US6048535A (en) * | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
WO2007072916A1 (ja) * | 2005-12-22 | 2007-06-28 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 卵内接種用ワクチン |
WO2010037027A2 (en) * | 2008-09-26 | 2010-04-01 | Auburn University | Immunization of avians by mucosal administration of non-replicating vectored vaccines |
CA2744348C (en) | 2008-11-19 | 2017-02-14 | Laboratorio Avi-Mex, S.A. De C.V. | Recombinant inactivated viral vector vaccine |
WO2016020730A1 (es) * | 2014-08-08 | 2016-02-11 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
WO2017008154A1 (en) * | 2015-07-10 | 2017-01-19 | University Of Guelph | Fowl adenovirus 9 (fadv-9) vector system and associated methods |
-
2014
- 2014-08-08 WO PCT/IB2014/063809 patent/WO2016020730A1/es active Application Filing
-
2015
- 2015-08-06 CN CN201580042608.3A patent/CN106661592A/zh active Pending
- 2015-08-06 US US15/502,443 patent/US10758608B2/en active Active
- 2015-08-06 EA EA201790296A patent/EA038951B1/ru unknown
- 2015-08-06 JP JP2017526775A patent/JP2017526737A/ja active Pending
- 2015-08-06 CA CA2956997A patent/CA2956997A1/en active Pending
- 2015-08-06 PE PE2017000180A patent/PE20170429A1/es unknown
- 2015-08-06 PE PE2022001034A patent/PE20221792A1/es unknown
- 2015-08-06 KR KR1020177006378A patent/KR20170063552A/ko not_active IP Right Cessation
- 2015-08-06 WO PCT/IB2015/055994 patent/WO2016020885A1/es active Application Filing
- 2015-08-06 MX MX2017001742A patent/MX2017001742A/es unknown
- 2015-08-06 EP EP15829016.3A patent/EP3178938A4/en not_active Withdrawn
- 2015-08-06 BR BR112017002577-9A patent/BR112017002577A2/pt active Search and Examination
- 2015-08-07 AR ARP150102532A patent/AR101468A1/es active IP Right Grant
-
2017
- 2017-02-03 PH PH12017500216A patent/PH12017500216B1/en unknown
- 2017-02-07 MX MX2022000718A patent/MX2022000718A/es unknown
- 2017-02-07 MX MX2022003590A patent/MX2022003590A/es unknown
- 2017-02-20 CO CONC2017/0001614A patent/CO2017001614A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2017001614A2 (es) | 2017-07-28 |
WO2016020730A1 (es) | 2016-02-11 |
CN106661592A (zh) | 2017-05-10 |
EA201790296A1 (ru) | 2017-06-30 |
US10758608B2 (en) | 2020-09-01 |
EA038951B1 (ru) | 2021-11-15 |
EP3178938A4 (en) | 2018-03-21 |
WO2016020885A1 (es) | 2016-02-11 |
CA2956997A1 (en) | 2016-02-11 |
MX2022000718A (es) | 2022-02-24 |
BR112017002577A2 (pt) | 2018-02-27 |
PE20170429A1 (es) | 2017-05-11 |
JP2017526737A (ja) | 2017-09-14 |
US20170232096A1 (en) | 2017-08-17 |
PH12017500216A1 (en) | 2017-07-03 |
PH12017500216B1 (en) | 2017-07-03 |
MX2017001742A (es) | 2017-05-15 |
PE20221792A1 (es) | 2022-11-25 |
EP3178938A1 (en) | 2017-06-14 |
MX2022003590A (es) | 2022-05-26 |
KR20170063552A (ko) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
CO2018005258A2 (es) | Vacuna del virus herpes simple | |
CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
BR112018012873A2 (pt) | vacina de vírus zika | |
MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
AR110632A1 (es) | Vectores del adenovirus canino | |
CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
AR071220A1 (es) | Astrovirus aviario depositado bajo el nuero cncm i-3895 | |
BR112015006763B1 (pt) | Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante | |
ES2609847T3 (es) | Vacunas de herpesvirus basadas en vectores del virus de la enfermedad de Newcastle | |
BR112018012642A2 (pt) | vacina de calicivírus felino | |
WO2015134368A3 (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
AR101840A1 (es) | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene | |
EA201990711A1 (ru) | Новый ehv сайт инсерции orf70 | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
CO2018001339A2 (es) | Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados | |
UY36162A (es) | COMPLEJO DE POLIPROTEÍNAS INMUNOGÉNICAS DE M. hyopneumoniae y GEN SINTÉTICO CODIFICANTE DEL COMPLEJO DE POLIPROTEÍNAS INMUNOGÉNICAS DE M. hyopneumoniae | |
EA201990719A1 (ru) | Новые промоторы | |
BR112012029633A8 (pt) | Vetores do parapoxvírus contendo antígeno do vírus da raiva. | |
CL2013002723A1 (es) | Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto. | |
BR112018000037A2 (pt) | partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina | |
MX2019007924A (es) | Vacunas contra la influenza. | |
CL2020000606A1 (es) | Sistema de expresión de paramyxoviridae. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |